

GENERAL

- Update of the first analysis from December 2008 (n=200) and December 2009 (n=385)
- The Novalung Clinical Support Team generally assists in the first application of the iLA Membrane Ventilator® or in difficult clinical cases
- Patient population:
 - Slight increase of ARDS patients especially due to H1N1 pandemic during winter 2009/2010
 - Application in exacerbated COPD patients meanwhile routine; acute-on-chronic patients is the second largest subgroup


Sub group	Registry 07/2010 (n=500)	Registry 12/2009 (n=385)	Registry 12/2008 (n=200)
ARDS total	268 (53.6 %)	197 (46.5 %)	132 (66 %)
- of which analogous to Villar et al.*	2	1	
- of which analogous to Terragni et al.**	7	5	
Acute on chronic	125 (25 %)	98 (25.5 %)	6 (3 %)
- of which exacerbated COPD	84 (16.8 %)	57 (14.8 %)	
- other acute on chronic	41 (8.2 %)	41 (10.5 %)	
Weaning Support	14 (2.8 %)	8 (2.1 %)	0
Increased intracranial pressure	9 (1.8 %)	6 (1.6 %)	2 (1 %)
Bronchopleural fistula	24 (4.8 %)	17 (4.4 %)	4 (2 %)
Bridge to Lung Transplant	7 (1.4 %)	6 (1.6 %)	2 (1 %)
Others	58 (11.6 %)	53 (13.7 %)	24 (27 %)

* Criteria analogous to Villar J et al. Crit Care Med 2006;34:1311-1318.

** Criteria analogous to Terragni PP et al. Anesthesiology 2009;111:826-834.


CONFIRMATION OF EFFECTIVENESS DATA

- Rapid normalization of the gas exchange:
CO₂ on average 58 mmHg within 4 hours
- Rapid reduction of the invasiveness of ventilation towards physiological respiratory parameters, promoting earlier spontaneous breathing




OUTCOME IMPROVEMENT


- Early use of the iLA Membrane Ventilator[®] confirmed: **42% higher survival rate** if therapy started within 48 hours after intubation!



- Reduced time on ventilator if therapy started within 48 hours after intubation: absolute **reduction of 2.5 ventilation days** with early use!



- Significantly **lower mortality** in exacerbated COPD:



Participate in the iLA[®] Registry and be a part of the iLA[®] study group!

* Hill SN et al. Lung Biology in health and disease: Ventilatory management strategies for critical care 1st ed. New York: Marcel Dekker Inc.; 2001:1-833

